EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
Kyverna Therapeutics has laid the foundations for the next major IPO of 2024. Having filed last month, the autoimmune cell therapy biotech set the terms for an offering that could gross around $180 ...
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapies "On the heels of recent ...
The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis. "We have seen firsthand the transformative effects of KYV-101 in MG patients treated ...
Credit: Getty Images. KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to KYV-101 for the ...
New Delhi: The National Highways Authority of India (NHAI) on Thursday announced to discontinue the Know Your Vehicle (KYV) process for cars for all new FASTag issuances, with effect from February 1, ...
(MENAFN- IANS) New Delhi, Jan 1 (IANS) The National Highways Authority of India (NHAI) on Thursday announced to discontinue the Know Your Vehicle (KYV) process for cars for all new FASTag issuances, ...
Hosted on MSN
NHAI discontinues KYV requirement for new car FASTags from February 1 — Check what’s changing
The National Highways Authority of India (NHAI) has announced the cessation of the Know Your Vehicle (KYV) procedure for issuing new FASTag orders for the Car/Jeep/Van category, effective from 1 ...
The investigational therapy will be used in Kyverna's KYSA-6 Phase 2 open-label, multicenter study to evaluate KYV-101 in adult patients with myasthenia gravis This is the fifth IND clearance for ...
NHAI has implemented a solid validation process that will have to be carried out before the activation of FASTag in order to strike a balance between convenience and system accuracy. The improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results